COMMUNIQUÉS West-GlobeNewswire

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
06/03/2024
Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and [...]
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
06/03/2024
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results 2023 revenue grew by 89% to $70.2 million; excluding GPS, revenues up 42% 2023 gross margin expanded by 10.7 percentage points over prior year [...]
Nurix Therapeutics to Participate in Upcoming Investor Conferences
06/03/2024
SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer [...]
ACTG CROI Presentation Demonstrates Superiority of HepB-CpG Vaccine Over Conventional Hepatitis B Vaccine Among People Living With HIV Who Have Not Previously Responded to Vaccination
06/03/2024
LOS ANGELES, March 06, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today made the oral presentation “HepB-CpG Vaccine is Superior to HepB-alum in People [...]
Health Systems near their breaking point. Labor costs continue to increase while dollars collected from payers decrease.
06/03/2024
CHICAGO, March 06, 2024 (GLOBE NEWSWIRE) -- Eighty four percent of health systems cite lower reimbursement from payers as a top cause of low operational margins, according to a report published by the Healthcare [...]
Merus annonce la publication d’un résumé qui sera présenté à la réunion annuelle 2024 de l’AACR : Zeno est efficace dans le traitement des modèles de cancer avec une forte expression du gène NRG1
06/03/2024
Présentation de l’affiche : lundi 8 avril 2024, de 9 h à 12 h 30, heure du Pacifique UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 06 mars 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société [...]
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
06/03/2024
PRESS RELEASE TWO NEW FINANCIAL ANALYSIS FIRMS INITIATE COVERAGE OF AB SCIENCE Paris, March 6, 2024, 8.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces that two financial analysis firms, DNA Finance and [...]
AB Science annonce l’initiation de la couverture de son titre par deux sociétés d’analyse financières, DNA Finance d’une part, et par In Extenso Finance d’autre part
06/03/2024
COMMUNIQUE DE PRESSE DEUX NOUVELLES SOCIETES D’ANALYSE FINANCIERE INITIENT LA COUVERTURE DU TITRE AB SCIENCE Paris, 6 mars 2024, 20h15 AB Science SA (Euronext - FR0010557264 - AB) annonce l’initiation de la couverture [...]
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into [...]
ACTG Presents Study at CROI Demonstrating Efficacy of Long-Acting Injectable Treatment Among People Who Had Previously Been Unable to Maintain Viral Suppression on Daily Oral Medication
06/03/2024
LOS ANGELES, March 06, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented the oral abstract “Long-Acting Injectable CAB/RPV is Superior to Oral [...]
NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research
06/03/2024
NMDP also recognizes its first Barbara Buchbinder Nurse Research Grant recipient, helping improve patient experience and outcomes MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- NMDP℠ announced two recipients of its Amy [...]
Robot-Assisted Dental Implant Placement Most Accurate and Precise Treatment Modality According to Landmark Study by Leading Oral Surgeon
06/03/2024
Dr. Jay Neugarten, an international thought leader in implant dentistry and early adopter of dental robotics, publishes clinical study on the unparalleled accuracy and precision of dental implantation assisted by the [...]
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
06/03/2024
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
06/03/2024
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the AdaptiSeal ™ [...]
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
06/03/2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe [...]
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
06/03/2024
50% Lesion clearance and regression of Herpes Zoster Neuralgia within 48 – 72 hours BOSTON, MASSACHUSETTS, March 06, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. ( BIXT ), (the “Company”), a clinical stage biotechnology [...]
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
06/03/2024
Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology [...]
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
06/03/2024
-- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Court Ruling creates [...]
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
06/03/2024
Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen 1 [...]

Pages